A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Bristol-Myers Squibb
Study ID
NCT02387996
Phase
PHASE2
Status
Completed

Conditions

  • Various Advanced Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose the study is to measure the effect of nivolumab (BMS-936558) in reducing tumor size in subjects with metastatic or unresectable bladder cancer.

Key Dates

Start date
Mar 9, 2015
Status verified
Oct 2022
Primary completion
Apr 15, 2016
Completion
Nov 12, 2021

Study Design

Enrollment
270 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Nivolumab
    Nivolumab intravenous infusion as specified

Primary Outcome Measure

Objective Response Rate Per BIRC Assessment [ Time Frame: From the date of first dose to the date of objectively documented progression or the date of subsequent therapy, whichever occurs first (assessed up to 14 months) ]

Locations (19)

FacilityCityStateZIPSite coordinators
Local Institution - 0013PhoenixArizona85054-
Local Institution - 0012DuarteCalifornia91010-3000-
Pacific Hematology Oncology AssociatesSan FranciscoCalifornia94115-
Local Institution - 0016AuroraColorado80045-
University Cancer Blood CtrAthensGeorgia30607-
Ft. Wayne Med Onco-Hema IncFort WayneIndiana46804-
Local Institution - 0030IndianapolisIndiana46202-
Local Institution - 0052Iowa CityIowa55242-
Crescent City Research Consortium, LLCMarreroLouisiana70072-
Karmanos Cancer InstituteDetroitMichigan48201-2014-
GU Research Network, LLCOmahaNebraska68130-
Local Institution - 0028New YorkNew York10029-
Local Institution - 0004CharlotteNorth Carolina28204-
Local Institution - 0051PortlandOregon97213-
Local Institution - 0029PhiladelphiaPennsylvania19111-2412-
Local Institution - 0059PittsburghPennsylvania15212-0000-
Erlanger Oncology & Hematology - Univ. of TNChattanoogaTennessee37404-
Local Institution - 0001HoustonTexas77030-
Local Institution - 0036SeattleWashington98101-

Find similar trials in Phoenix, AZ

By research site
Local Institution - 0013· Phoenix, AZLocal Institution - 0012· Duarte, CAPacific Hematology Oncology Associates· San Francisco, CALocal Institution - 0016· Aurora, COUniversity Cancer Blood Ctr· Athens, GAFt. Wayne Med Onco-Hema Inc· Fort Wayne, IN